161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Reports Second Quarter 2026 Financial Results and Business Highlights
News
Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million
Shareholder votes
Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
Reports First Quarter 2026 Financial Results and Business Highlights
Annual Report to Security Holders
Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)
Q2
Q1
FY 2024
Q3
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Notice of Exempt Offering of Securities
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report
Submission Upload
Correspondence